相关实验视频
Updated: Jun 11, 2025

07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
23.5K
GLP-1受体激动剂是一种转变性的预康复工具,用于在接受选择性修复的肥胖患者减肥
Graham J Spurzem1, Ryan C Broderick2, Patricia Ruiz-Cota2
1Department of Surgery, Division of Minimally Invasive Surgery, University of California San Diego, San Diego, CA, USA. gspurzem@health.ucsd.edu.
Surgical endoscopy
|October 5, 2024
概括
葡萄糖类-1 (GLP-1) 激动剂有助于肥胖患者在手术前更快地减肥. 这种方法可以加速手术准备,而不会增加术后并发症.
科学领域:
- 腹部外科 腹部外科
- 代谢手术 代谢手术
- 手术瘤学手术瘤学
背景情况:
- 肥胖是腹修复后并发症的重要危险因素.
- 葡萄糖类-1 (GLP-1) 受体激动剂越来越多地用于药理学体重管理.
- 这些药物可以帮助患者实现手术减肥目标.
研究的目的:
- 评估早期使用GLP-1激动剂的经验,结合在接受选择性修复的患者进行手术前减肥的生活方式改变.
- 为了比较使用GLP-1激动剂的患者和仅依赖生活方式改变的患者之间的结果.
主要方法:
- 在2014年至2023年期间,对接受选择性修复的肥胖患者进行了单一中心的回顾性审查.
- 在手术前,患者的目标是身体质量指数 (BMI) ≤33公斤/平方米.
- 对GLP-1治疗组与对照组进行比较,仅通过改变生活方式来实现类似的减肥.
主要成果:
- 确定了46名患者 (24名GLP-1,22名对照患者).
- 从GLP-1启动到手术的平均时间明显较短 (6.3个月),与对照组的手术初次诊所访问 (14.7个月) 相比.
- 两组之间在30天的发病率,死亡率,重新手术率或的复发率上没有发现显著差异.
结论:
- GLP-1激动剂有效地加速手术前的体重减轻在预定进行修复的肥胖患者.
- 使用GLP-1激动剂似乎不会对短期术后结果产生负面影响.
相关概念视频
Glucagon-like Receptor Agonists
302
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
302
Oral Hypoglycemic Agents: Glinides
143
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
143
Dipeptidyl Peptidase 4 Inhibitors
177
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
177
Oral Hypoglycemic Agents: Biguanides and Glitazones
181
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
181

